Member access

4-Traders Homepage  >  Shares  >  Mercato Continuo Espanol  >  Grifols SA    GRF   ES0171996012

GRIFOLS SA (GRF)

40
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Mercato Continuo Espanol
07/25/2014 07/28/2014 07/29/2014 07/30/2014 07/31/2014 Date
38.965(c) 38.9(c) 39.21(c) 39.31(c) 33.82(c) Last
631 745 729 480 517 225 606 571 4 614 121 Volume
+0.43% -0.17% +0.80% +0.26% -13.97% Change
More quotes
Company
Grifols SA operates as a fractionator of plasma derived blood products. The company operates through four segments: Bioessence, Hospital, Diagnostic and Raw Materials. The Bioessence segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital... 
Sector
Pharmaceuticals
Calendar
07/31Earnings Release
Surperformance© rating of Grifols SA
Trading Rating : Investor Rating :
More about the company
Chart GRIFOLS SA
Duration : Period :
Grifols SA Technical Analysis Chart | GRF | ES0171996012 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 3 519 M
EBIT 2014 980 M
Net income 2014 520 M
Debt 2014 3 151 M
Yield 2014 1,71%
Sales 2015 3 755 M
EBIT 2015 1 065 M
Net income 2015 593 M
Debt 2015 2 829 M
Yield 2015 2,09%
PER 2014 21,54
PER 2015 18,72
EV / Sales 2014 3,98x
EV / Sales 2015 3,65x
Capitalization 10 867 M
More Financials
Latest news on GRIFOLS SA
1d ago GRIFOLS : rsquo; net profit rises by 23% to 224.8 million euros in the First Hal..
4d ago HOLOGIC : GRIFOLS -New highly sensitive test to screen donors of blood, tissues,..
7d ago GRIFOLS : New highly sensitive test to screen donors of blood, tissues, and orga..
07/10 GRIFOLS : Therapeutics Assigned Patent
07/01 GRIFOLS : Award Winners at the Seventh Edition of the Martín Villar Research Awa..
06/30 GRIFOLS : improves safety of transfusions with its ID CORE XT diagnostic kit
06/30 GRIFOLS : Therapeutics Assigned Patent
06/23 GRIFOLS : launches a continuing education program for transfusion medicine profe..
06/18 GRIFOLS : opens state-of-the-art facility in Clayton, NC to help advance treatme..
06/14 ARADIGM : Reports Milestone Payment for Dosing of First Patient in Phase III Stu..
06/11 ARADIGM : Receives $5 Million Milestone For Dosing of the First Patient in Phase..
06/10 ARADIGM : Gets Milestone Payment for Dosing of First Patient in Phase III Study ..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
Grifols SA : Income Statement Evolution
More Financials
EPS Revisions
Grifols SA : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF